Global CAR T-Cell Therapy for Multiple Myeloma Market Size, Status and Forecast 2019-2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by CAR T-Cell Therapy for Multiple Myeloma Revenue
• 1.4 Market by Type
  • 1.4.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Monotherapy
  • 1.4.3 Combination Therapy
• 1.5 Market by Application
  • 1.5.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Application: 2020 VS 2026
  • 1.5.2 Multiple Myeloma
  • 1.5.3 Refractory or Relapsed Multiple Myeloma
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Perspective (2015-2026)
• 2.2 Global CAR T-Cell Therapy for Multiple Myeloma Growth Trends by Regions
  • 2.2.1 CAR T-Cell Therapy for Multiple Myeloma Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 CAR T-Cell Therapy for Multiple Myeloma Historic Market Share by Regions (2015-2020)
  • 2.2.3 CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 CAR T-Cell Therapy for Multiple Myeloma Market Growth Strategy
  • 2.3.6 Primary Interviews with Key CAR T-Cell Therapy for Multiple Myeloma Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top CAR T-Cell Therapy for Multiple Myeloma Players by Market Size
  • 3.1.1 Global Top CAR T-Cell Therapy for Multiple Myeloma Players by Revenue (2015-2020)
  • 3.1.2 Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Concentration Ratio
  • 3.2.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by CAR T-Cell Therapy for Multiple Myeloma Revenue in 2019
• 3.3 CAR T-Cell Therapy for Multiple Myeloma Key Players Head office and Area Served
• 3.4 Key Players CAR T-Cell Therapy for Multiple Myeloma Product Solution and Service
• 3.5 Date of Enter into CAR T-Cell Therapy for Multiple Myeloma Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global CAR T-Cell Therapy for Multiple Myeloma Historic Market Size by Type (2015-2020)
• 4.2 Global CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)
• 5.2 Global CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
• 6.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in North America (2019-2020)
• 6.3 North America CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
• 6.4 North America CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
• 7.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in Europe (2019-2020)
• 7.3 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
• 7.4 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)

8 China

• 8.1 China CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
• 8.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in China (2019-2020)
• 8.3 China CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
• 8.4 China CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
• 9.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in Japan (2019-2020)
• 9.3 Japan CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
• 9.4 Japan CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
• 10.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
• 10.4 Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)

11 India

• 11.1 India CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
• 11.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in India (2019-2020)
• 11.3 India CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
• 11.4 India CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
• 12.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in Central & South America (2019-2020)
• 12.3 Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
• 12.4 Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Juno Therapeutics
  • 13.1.1 Juno Therapeutics Company Details
  • 13.1.2 Juno Therapeutics Business Overview
  • 13.1.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Introduction
  • 13.1.4 Juno Therapeutics Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020))
  • 13.1.5 Juno Therapeutics Recent Development
• 13.2 Kite Pharma
  • 13.2.1 Kite Pharma Company Details
  • 13.2.2 Kite Pharma Business Overview
  • 13.2.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Introduction
  • 13.2.4 Kite Pharma Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020)
  • 13.2.5 Kite Pharma Recent Development
• 13.3 Novartis
  • 13.3.1 Novartis Company Details
  • 13.3.2 Novartis Business Overview
  • 13.3.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Introduction
  • 13.3.4 Novartis Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020)
  • 13.3.5 Novartis Recent Development
• 13.4 Collectis
  • 13.4.1 Collectis Company Details
  • 13.4.2 Collectis Business Overview
  • 13.4.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Introduction
  • 13.4.4 Collectis Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020)
  • 13.4.5 Collectis Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer